RLYB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rallybio Corp (RLYB) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The technical indicators suggest the stock is overbought, and the financial performance shows significant declines in revenue, net income, and EPS. Additionally, the stock's trend indicates a high probability of negative returns in the short to medium term. While the merger with Candid Therapeutics could be a positive catalyst, concerns over shareholder rights and potential legal issues add significant risk. Therefore, this stock is not suitable for the given investor profile.
The stock's MACD is positive and contracting, indicating a potential slowdown in bullish momentum. RSI is at 87.263, signaling an overbought condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is nearing resistance at R1: 10.814. The stock has a 70% chance of declining in the next day (-5.8%), week (-9.7%), and month (-17.34%).
The merger with Candid Therapeutics could enhance Rallybio's market competitiveness and expand its T-cell engager therapies for autoimmune diseases. Shares surged 27% following the merger approval.
Halper Sadeh LLC is investigating the merger for potential shareholder rights violations and federal securities law concerns. Financial performance has significantly deteriorated, with revenue, net income, and EPS showing steep YoY declines. The stock is overbought and has a high probability of negative returns in the short to medium term.
In 2025/Q3, revenue dropped by 29.10% YoY to $212,000. Net income declined by 239.68% YoY to -$16,016,000. EPS fell by 237.86% YoY to -2.84. Gross margin remained flat at 100%.
No analyst rating or price target changes provided.
